Discussions

To better serve the academic and commercial demands of our global clientele, Creative Biolabs has assembled a specialized team and a state-of-the-art technical platform for the production of non-IgG BsAbs. Our goal is to find more effective therapeutic antibodies.

We can help your bi-specific non-IgG antibody programs in many ways, from early bi-specific design and optimization to later manufacturing, thanks to our in-house non-IgG antibody platform and BsAb service system. Our skilled scientists begin with BsAb design (e.g., target binding, isotype selection, mode of action) in accordance with your specific requirements. Next, they optimize the BsAbs' properties (half-life, size, stability, etc.) and begin mass production (recombinant DNA technology, hybrid-hybridoma technology, isotype conversion, and conjugation).